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ABSTRACT
Objective To determine serum biomarker associations
with clinical response to golimumab treatment in patients
with psoriatic arthritis (PsA).
Methods GO–REVEAL was a randomised, placebo-
controlled study of golimumab in patients with active
PsA. Samples were collected from 100 patients at
baseline, week 4 and week 14, and analysed for serum-
based biomarkers and protein profiling (total 92 markers);
data were correlated with clinical measures at week 14.
Results Serum levels of a subset of proteins
(apolipoprotein C III, ENRAGE, IL-16, myeloperoxidase,
vascular endothelial growth factor, pyridinoline, matrix
metalloproteinase 3, C-reactive protein (CRP),
carcinoembryonic antigen, intercellular adhesion molecule
1 and macrophage inflammatory protein 1α) at baseline
or week 4 were strongly associated with American
College of Rheumatology 20% improvement (ACR20)
response and/or disease activity score in 28 joints
(DAS28) at week 14. A smaller subset of proteins was
significantly associated with a 75% improvement in the
psoriasis area and severity index score (PASI75) at
week 14, (adiponectin, apolipoprotein CIII, serum
glutamic oxaloacetic transaminase, and tumour necrosis
factor α). Subsets of proteins were identified as
potentially predictive of clinical response for each of the
clinical measures, and the power of these biomarker
panels to predict clinical response to golimumab
treatment was stronger than for CRP alone.
Conclusions This analysis provides insight into several
panels of markers that may have utility in identifying PsA
patients likely to have ACR20, DAS28, or PASI75
responses following golimumab treatment.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, inflammatory
joint disease involving synovial tissue, enthesitis
and skin,1 and is associated with elevated serum
and tissue levels of markers of inflammation and
bone metabolism. Some pro-inflammatory cyto-
kines including interleukin (IL)-1, IL-6, IL-15, IL-18
and tumour necrosis factor-like weak inducer of
apoptosis (TWEAK)2 have been reported to be
abundantly expressed in the synovium of PsA
patients.3 4 Serum levels of TWEAK were shown to
correlate with matrix metalloproteinase (MMP)-3
and disease activity score in 28 joints (DAS28)
using the C reactive protein (CRP) level scores in
patients with PsA.5 6 Serum MMP-3 levels have
been modulated following anti-tumour necrosis
factor (TNF)α therapy in PsA.7 Markers of inflam-
mation such as CRP correlated with markers of
bone remodelling (C-telopeptide of type I collagen
(CTX-1) and deoxypyridinoline (DPD))8 in PsA,
and macrophage colony-stimulating factor and
receptor activator of nuclear factor κβ ligand
(RANKL) have also been correlated with radio-
graphic progression and joint space narrowing.9
These data suggest that both inflammatory and
bone remodelling processes are activated in patients
with active PsA.
We recently assessed the safety and efficacy of goli-
mumab treatment (a human monoclonal antibody
to TNFα) in a phase III study of active PsA.10 We
sought to identify biomarkers associated with clin-
ical progression or therapeutic response in skin and
articular compartments. We analysed approximately
100 different serum proteins using multiplex and
single-plex assay platforms (ELISA and Luminex) to
identify markers modulated by golimumab treat-
ment in patients with active PsA. Comparisons of
baseline markers, along with change from baseline
to week 4, were evaluated against several clinical
response measures including the American College
of Rheumatology 20% improvement (ACR20)
response, DAS28 and 75% improvement in the psor-
iasis area and severity index score (PASI75), which
assesses response of skin lesions, with the intent to
understand the relationships between the markers
and specific aspects of PsA.
MATERIALS AND METHODS
The primary results of the GO–REVEAL trial have
previously been published.9 Briefly, adult patients
with active PsA, despite previous therapy with
disease-modifying antirheumatic drugs or non-
steroidal anti-inflammatory drugs, were enrolled in
this study. Patients were assigned in a ratio of 1 :
1.3 : 1.3 to receive subcutaneous injections of
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placebo (n=113), golimumab 50 mg (n=146), or golimumab
100 mg (n=146) every 4 weeks through week 20. For this ana-
lysis, the golimumab groups were combined into a single group
and compared against the placebo group. The primary endpoint
was the proportion of patients with ACR20 response at week
14, DAS28 using CRP- see primary paper and PASI75 were sec-
ondary endpoints.10
In this prospectively planned GO–REVEAL biomarker sub-
study, analyses were conducted for the first 100 patients, at
selected study sites, who had sera obtained at weeks 0, 4 and 14.
The evaluated markers were chosen based on biomarker pub-
lications in PsA and previous experience in TNF-mediated auto-
immune diseases including rheumatoid arthritis (RA) and PsA.
Specific individual markers were chosen as well as a Rules
Based Medicine Human MAP panel of markers and all assays
met a variety of assay validation criteria. Serum was collected
by standard methods and frozen at −70°C at the site before
shipment to the central and speciality laboratories for batched
testing. Samples were tested by Quintiles Laboratories
(Marietta, Georgia, USA), Pacific Biomarkers (Seattle,
Washington, USA) and Rules Based Medicine (Austin, Texas,
USA); data were sent to Elashoff Consulting (Redwood City,
California, USA) for statistical analysis. All 92 biomarkers had
an established lower limit of quantification and met specified
data inclusion criteria (eg, ≥20% of all samples for a given
marker had to be above the lower limit of quantification for
that assay). Biomarkers that were undetectable at baseline were
excluded from subsequent data analyses. Robust linear regres-
sion models were used to test for the association of combined
biomarker panels with multiple clinical endpoints. To account
for multiple statistical testing, a false discovery rate (FDR) ana-
lysis was performed. The FDR analysis was used to define a p
value threshold at which the FDR would be approximately 5–
10%, and accounts for the fact that the biomarkers studied
were not independent as demonstrated by marker-to-marker
correlations. Prediction models were developed using logistic
regression methods. The criteria for inclusion of data and statis-
tical analysis methods were recently described in two similar
golimumab biomarker studies.11 12
RESULTS
Of the 92 analytes, 30 markers were not detectable at baseline
and 62 met the criterion for inclusion and were analysed
further. Overall, baseline biomarker levels were similar between
the placebo and golimumab treatment groups and only four
markers (brain-derived neurotrophic factor, insulin, TNF RII
and intercellular adhesion molecule (ICAM)-1) were signifi-
cantly different between the placebo and golimumab treatment
groups at baseline (data not shown).
Biomarker changes over time
In the golimumab-treated group, multiple markers showed sig-
nificant change from baseline to week 4. Figure 1 shows a heat
map representation of markers in which the mean change from
baseline at weeks 4 or 14 was significantly different between
the two treatment groups. In general, golimumab treatment
decreased levels of many biomarkers from baseline to week 14,
with stable or slightly increasing levels of markers in the
placebo group. In golimumab-treated patients, the levels of
acute phase reactants (serum amyloid P, haptoglobin, α 1 anti-
trypsin), inflammatory markers (monocyte/macrophage derived
chemokine, macrophage inflammatory protein (MIP)-1β, IL-8,
IL-16, ENRAGE (also known as S100A12), ICAM-1, MMP-3,
Monocyte chemotactic protein-1 (MCP-1), vascular endothelial
growth factor (VEGF)), and other proteins (PAI-1, thyroxine
binding globulin) were significantly decreased at weeks 4 and
14 compared with placebo-treated patients. Golimumab
Table 1 Baseline demographics
Placebo Golimumab 50 mg Golimumab 100 mg Combined golimumab
Overall population
n 113 146 146 292
Age (years) 47 (40, 54) 44 (38, 54) 50 (39, 56) 47 (38.5, 55)
Weight (kg) 86.3 (70, 96.8) 80.7 (69.3, 94.3) 84.6 (71.6, 99.2) 82.9 (70.2,96.9)
Sex (% male) 61% 61% 59% 60%
Race (% Caucasian) 97% 97% 97% 97%
CRP (mg/ml) 0.6 (0.3, 1.3) 0.6 (0.3, 1.6) 0.6 (0.3, 1.7) 0.6 (0.3, 1.6)
Methotrexate use (% yes) 48% 49% 47% 48%
Swollen joint count 13.4±9.8 14.1±11.4 12±8.5 13±10.1
Tender joint count 21.9±14.7 24±17.1 22.5±15.7 23.3±16.4
PASI 6.52±6.83 7.85±8.14 8.76±9.13 7.81±8.22
Biomarker substudy population
N 26 39 35 74
Age (years) 42.5 (36, 53.5) 47 (41, 52.5) 52 (43, 56.5) 48.5 (42, 55.8)
Weight (kg) 87.3 (71.2, 96.8) 88 (79.2, 103.5) 95.4 (76.4, 104.7) 90 (79, 104)
Sex (% male) 54% 67% 60% 64%
Race (% Caucasian) 96% 92% 94% 93%
CRP (mg/ml) 0.6 (0.3, 1.3) 0.6 (0.3, 1.2) 0.9 (0.4, 2.1) 0.6 (0.3, 1.4)
Methotrexate usage (% yes) 38% 33% 37% 35%
Swollen joint count 11.8±8.7 13±7.4 10.3±4.9 11.7±6.4
Tender joint count 20.7±12.5 21.1±13 21±10.5 21.1±11.8
PASI 5.67±4.26 7.77±6.38 9.80±9.20 7.93±7.20
Data are presented as median (IQR) or mean±SD unless otherwise noted.
CRP, C-reactive protein; PASI, psoriasis area and severity index.
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treatment also improved CRP levels relative to placebo. In con-
trast, less pronounced changes were observed in the placebo
group.
Comparison of clinical endpoints between placebo and
combined golimumab groups in the biomarker substudy
In the biomarker substudy, 6.5% of patients in the placebo
group achieved ACR20 response at week 14, compared with
55.1% of patients in the combined golimumab group. In add-
ition, a higher percentage (48.0%) of patients in the combined
golimumab group achieved a PASI75 response at week 14 com-
pared with patients in the placebo group (9.5%). Likewise,
there was a greater decrease in the mean DAS score in the com-
bined golimumab group compared with those in the placebo
group, −1.47 and −0.11, respectively. Comparison of the sub-
study with the overall study population indicated comparable
clinical benefit following golimumab treatment in each of these
efficacy measures.10
Biomarker correlations with clinical endpoints
The biomarkers (baseline levels and change from baseline to
week 4) were evaluated for association with ACR20, DAS28,
and PASI75 at week 14 using a logistic regression analysis
(table 2). Only biomarkers with a significant association to at
least one of the clinical measures are shown. Baseline levels of
adiponectin, prostatic acid phosphate (PAP) and VEGF were sig-
nificantly associated with two clinical endpoints, while no
markers were significantly associated with all three measures.
As shown in table 2, various other baseline markers were sig-
nificantly associated with only one clinical measure.
Interestingly, most of the identified markers were associated
with DAS28, and relatively few correlated with ACR20 or
PASI75.
Biomarker changes from baseline to week 4 were also corre-
lated with clinical measures at week 14. A similar pattern was
observed, there were more associations with DAS28 than with
ACR20 or PASI75, and none of the markers correlated across all
three endpoints. Only the change in cancer antigen 125, IL-16,
PAP and serum glutamic oxaloacetic transaminase (SGOT)
levels correlated with two clinical endpoints, although other
analytes correlated with a single endpoint. ENRAGE, IL-16,
myeloperoxidase, PAP and VEGF consistently correlated with
ACR20 and/or DAS28 endpoints, with both baseline and
change from baseline to week 4 biomarker results.
The placebo group had no significant associations between
biomarkers and any clinical endpoints except for a correlation
between change from baseline to week 4 in MIP-1β with
DAS28 at week 14 (data not shown).
Biomarker prediction of clinical endpoints
Combined baseline biomarker panels were evaluated for their
potential to predict clinical response at week 14 using a logistic
regression model (table 3). Pyridinoline, adiponectin, PAP and
factor VII were identified as a panel of markers that have the
potential to be predictive of ACR20 response at week 14 (speci-
ficity 65%, sensitivity 85%). Similarly, adiponectin, factor VII,
SGOT, IgA and leptin were identified as potentially predictive
of DAS28 response (specificity 71%, sensitivity 90%).
Adiponectin, factor VII and IL-16 indicated prediction of
PASI75 response (specificity 63%, sensitivity 76%). Both adipo-
nectin and factor VII appeared in the prediction models for all
three clinical endpoints.
Figure 1 Heat map profile of serum markers in which the changes at week 4 or 14 were significantly different in patients treated with golimumab
versus placebo. IL, interleukin; ICAM, intercellular adhesion molecule; MCP, monocyte chemotactic protein-1; MDC, macrophage-derived chemokine;
MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; PAI-1; plasminogen activator inhibitor 1; VEGF, vascular endothelial growth
factor.
Ann Rheum Dis 2013;72:83–88. doi:10.1136/annrheumdis-2012-201697 85
Clinical and epidemiological research
 group.bmj.com on February 12, 2013 - Published by ard.bmj.comDownloaded from 
The data for CRP as a single analyte are shown for compari-
son to the biomarker panels as well as to the individual
markers identified in the predictive panels for ACR20, DAS28
and PASI75 at week 14. The predictive power of the biomarker
panels was stronger than for CRP alone for each of the
endpoints.
DISCUSSION
This biomarker substudy of GO–REVEAL showed that golimu-
mab treatment is effective in modulating specific acute-phase
reactants, inflammatory markers, metabolic factors, bone
remodelling markers and other selected proteins compared with
placebo. Due to the varied assessments used to measure
improvement in PsA, it is not surprising that no individual
marker significantly correlated with all three clinical measures.
However, as shown in table 2, the odds ratios (OR) for several
of the identified markers showed strong associations with two
of the clinical measures (DAS28 and ACR20) at week 14.
In the current study, serum levels of a subset of proteins
(apolipoprotein CIII, ENRAGE (S100A12), IL-16, myeloperoxi-
dase, VEGF, pyridinoline, MMP-3, CRP, carcinoembryonic
antigen, ICAM-1 and MIP-1α) at baseline or week 4 were
strongly associated with ACR20 and/or DAS28 scores at week
14. Several of these markers including CRP, VEGF, MMP-3 and
ICAM-1 have been previously identified to correlate with clin-
ical endpoints in RA following anti-TNF treatment,12 suggest-
ing biological similarities in some disease processes, especially
among PsA patients with polyarticular peripheral arthritis. In a
recent study, levels of IL-6, VEGF, MMP-3 and YKL-40 were sig-
nificantly associated with clinical response to anti-TNFα ther-
apies in patients with spondyloarthropathies.13 In RA, high
baseline levels of urinary pyridinoline/DPD ratio are predictive
of joint damage and are thought to reflect alterations in the
bone tissue matrix, and these markers might also have signifi-
cance in PsA.14 15
A few markers at baseline were significantly associated with
PASI75 at week 14 including adiponectin, apolipoprotein CIII,
SGOT and TNFα. In addition, both IL-16 and ENRAGE
(S100A12) levels were strongly associated with DAS28 and/or
ACR20 at week 14 in golimumab-treated PsA patients. Several
of these markers have been identified to be of particular inter-
est. IL-16 has been shown to be induced in synovial fibroblasts
from RA patients, independent of nuclear factor κB signal-
ling.16 In addition, IL-17 can increase levels of IL-16 messenger
RNA by RA fibroblast-like synoviocytes and peripheral blood
mononuclear cells.17 Given the proposed role of IL-17 in spon-
dylarthropathies,18 it is possible that there is a synergy with
IL-16 and IL-17 to perpetuate rheumatological disease pro-
cesses. Elevated levels of ENRAGE (S100A12) have been
observed in both tissue and peripheral blood of PsA patients
and can be modulated by treatment with methotrexate.19 The
associations observed with adiponectin are intriguing relative
to the effect of obesity on clinical outcomes and response to
therapy in several systemic inflammatory autoimmune condi-
tions, including PsA. In RA, adiponectin levels correlate with
disease severity.20 Also, coordinated roles for adiponectin, leptin
and visfatin are suggested in the modulation of the inflamma-
tory environment in patients with RA.21 It could be that these
adipokines play a similar role in PsA and can be downregulated
by TNF inhibition. Nevertheless, the available data regarding
the effects of anti-TNF treatments on adiponectin levels in RA
are often conflicting.
We also explored whether CRP alone or in a combination of
markers could significantly predict clinical response to golimu-
mab treatment in patients with PsA. In combination with
other markers, CRP did not improve the prediction of clinical
response over the biomarker panels identified without CRP.
Different combinations of markers including, pyridinoline, adi-
ponectin, PAP, factor VII, IL-16, SGOT, IgA and/or leptin were
found to be predictive of ACR20, DAS28, or PASI75 response to
golimumab treatment. Baseline levels of adiponectin and factor
VII with other markers were significantly associated with all
three evaluated clinical measures. The only markers indentified
as potential predictive markers for PASI75 response at week 14
were IL-16, adiponectin and factor VII. The sensitivity and spe-
cificity of these combinations were stronger than CRP alone in
predicting clinical response.
Table 2 Odds Ratios (OR) from robust logistic regression analysis
testing the association between biomarker levels (baseline and changes
from baseline to week 4) and clinical endpoints with at least one
significant association at week 14 in the golimumab group
ACR20 DAS28 PASI75
Biomarker OR p Value OR p Value OR p Value
Baseline
Adiponectin 1.681 NS 2.296 0.019 1.969 0.035
Apolipoprotein CIII 0.865 NS 1.459 NS 2.397 0.048
ENRAGE 1.133 NS 2.455 0.006 0.717 NS
IgA 1.013 NS 1.849 0.023 1.279 NS
IGF-1 1.234 NS 1.668 NS 0.272 0.015
IL-16 0.858 NS 2.330 0.028 1.063 NS
Insulin 0.803 NS 0.706 0.018 0.876 NS
Myeloperoxidase 1.323 NS 1.743 0.019 0.720 NS
PAP 2.528 0.034 2.761 0.021 0.927 NS
SGOT 0.536 NS 0.274 0.001 1.471 NS
VEGF 1.665 0.042 2.338 0.008 1.133 NS
Pyridinoline 0.198 0.008 0.344 NS 0.777 NS
MMP-3 1.115 NS 1.264 NS 0.509 NS
Change from baseline to week 4
CRP 0.708 0.038 0.700 NS 0.851 NS
Cancer antigen 125 0.286 0.034 0.293 0.046 0.929 NS
Carcinoembryonic Antigen 0.054 0.024 0.341 NS 0.461 NS
CD40 0.516 NS 0.265 0.040 2.171 NS
CD40 ligand 0.773 NS 0.558 0.027 1.100 NS
ENRAGE 0.589 0.029 0.622 NS 1.319 NS
ICAM-1 0.387 NS 0.178 0.028 2.280 NS
IL-16 0.305 0.047 0.191 0.016 1.224 NS
MDC 0.118 0.009 0.324 NS 0.233 NS
MIP-1α 0.976 NS 0.319 0.015 1.033 NS
MIP-1β 0.544 NS 0.127 0.009 0.899 NS
Myeloperoxidase 0.806 NS 0.589 0.014 1.077 NS
PSA-free 0.343 NS 0.167 0.025 0.604 NS
PAP 0.220 0.009 0.144 0.003 1.243 NS
SGOT 1.150 NS 2.251 0.040 0.459 0.044
TNF receptor II 0.158 NS 0.090 0.032 0.500 NS
VEGF 0.395 NS 0.196 0.009 1.836 NS
TNFα serum 0.592 NS 0.400 NS 0.039 <0.001
ICAM-1 0.055 0.044 0.235 NS 0.428 NS
Values were significant if they were p<0.05.
ACR20, American College of Rheumatology 20% improvement response; CRP,
C-reactive protein; DAS28, disease activity score in 28 joints; ICAM, intercellular
adhesion molecule; IL, interleukin; IG, immunoglobulin; MDC, monocyte/
macrophage-derived chemokine; MIP-1, macrophage inflammatory protein 1; MMP,
matrix metalloproteinase; NS, not significant; PAP, prostatic acid phosphatase; PSA,
prostate-specific antigen; PASI75, 75% improvement in the psoriasis area and
severity index score; SGOT, serum glutamic oxaloacetic transaminase; TNF, tumour
necrosis factor; VEGF, vascular endothelial growth factor.
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This analysis identified several panels of markers that may be
predictive of ACR20, DAS28, or PASI75 responses. The goal of
including this broad panel of markers was to evaluate potential
new markers not previously known for their associations with
PsA disease or TNF-mediated disease processes. Although these
analyses included nearly 100 markers for comparison with clin-
ical efficacy measures, there may well be other analytes that
could show even stronger correlations, including some that
indicate disease healing or repair. It is not surprising that differ-
ent panels of markers were identified given the unique informa-
tion captured in these clinical assessments evaluating either
skin or joint involvement. As this was a hypothesis-generating
evaluation of a panel of markers that may be predictive, it is
recognised that these observations would need to be confirmed
in an independent study. However, these results can provide a
valuable foundation for subsequent biomarker comparisons in
the PsA population. Insights from this study have suggested
new combinations of markers that may have utility in under-
standing the relevance of changes in the inflammatory pro-
cesses that occur in the skin and joints of PsA patients in
response to golimumab treatment.
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Table 3 Logistic regression model comparing baseline CRP and baseline combined biomarker panels in predicting clinical response to golimumab
treatment at week 14
ACR20* response DAS28† response PASI75* response
Model (true/predicted)† NR R Accuracy‡ NR R Accuracy‡ N R Accuracy‡
Baseline biomarker panel† NR R Accuracy† NR R Accuracy† N R Accuracy†
Non-responder 26 14 Specificity: 65% 17 7 Specificity: 71% 31 18 Specificity: 63%
Responder 5 29 Sensitivity: 85% 5 45 Sensitivity: 90% 6 19 Sensitivity: 76%
Predictive value NPV 84% PPV 67% NPV 77% PPV 87% NPV 84% PPV 51%
Baseline CRP only†
Non-responder 28 12 Specificity: 70% 17 7 Specificity: 71% 21 28 Specificity: 43%
Responder 23 11 Sensitivity: 32% 25 25 Sensitivity: 50% 11 14 Sensitivity: 56%
Predictive value NPV 55% PPV 48% NPV 40% PPV 78% NPV 66% PPV 33%
Predictive panel§ Weight OR p Value Weight OR p Value Weight OR p Value
Pyridinoline −1.89 0.15 0.009 – – – – –
Adiponectin 1.00 2.72 0.010 1.19 3.29 0.015 0.69 1.99 0.046
Prostatic acid Phosphatase 1.51 4.53 0.011 – – – – – –
Factor VII −0.76 0.47 0.039 1.25 3.49 0.038 0.73 2.08 0.043
IL-16 – – – – – – −1.75 0.17 0.006
SGOT – – – −2.07 0.13 0.001 – – –
IgA – – – 0.92 2.51 0.010 – – –
Leptin – – – −0.66 0.52 0.016 – – –
*ACR20, PASI75 and DAS-28 were treated as categorical variables in this analysis. To be classified as a DAS28 responder, patients had to have a good or moderate response.10
†All biomarker values were log2-transformed before inclusion in the models.
‡Model accuracy (sensitivity, specificity, NPV, PPV) was estimated using cross-validation.
§Weights are the coefficients in the logistic regression model. OR are the exponential of the weights. Multivariate p values are based on inclusion of all terms in the model.
ACR20, American College of Rheumatology 20% improvement response; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; Ig, immunoglobulin; IL, interleukin;
NPV, negative predictive value; NR ,non-responders; PASI75, 75% improvement in the psoriasis area and severity index score; PPV, positive predictive value; R, responders;
SGOT, serum glutamic oxaloacetic transaminase.
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